Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ciclosporin · 2 trials · 1 indication
| Name | Type | Description |
|---|---|---|
| ciclosporin | DRUG | - |
Inclusion Criteria: * \- Appropriate the definition/diagnosis criteria of atopic dermatitis of the Japanese Dermatological Association * Patients with severest atopic dermatitis \[according to the "Guidelines for Treatment of Atopic Dermatitis 2002, the severity of atopic dermatitis will be classif...
Ciclosporin is used for the treatment of severe atopic dermatitis. It is a small molecule being developed by Novartis AG. The drug is currently in Phase 3 clinical development for this dermatological condition, with two completed Phase 3 trials evaluating its safety and efficacy.
Ciclosporin works by suppressing the immune system, specifically by inhibiting the activity of T-cells, which are involved in the inflammatory response that contributes to atopic dermatitis. This mechanism helps reduce the skin inflammation and itching associated with severe atopic dermatitis.
Ciclosporin is developed by Novartis AG, a multinational pharmaceutical company. Novartis is listed on the stock exchange under the ticker symbol NVS. The company is conducting clinical trials to evaluate ciclosporin for the treatment of severe atopic dermatitis.
Ciclosporin is in Phase 3 clinical development for severe atopic dermatitis. It is an investigational drug and has not yet been approved by regulatory authorities. Two Phase 3 trials have been completed, but the drug remains in clinical development.
Ciclosporin has been studied in two Phase 3 clinical trials for severe atopic dermatitis. These are NCT00232063, a long-term study, and NCT00232076, a verification study. Both trials have been completed and enrolled participants aged 20 years and older.
Ciclosporin is the same as cyclosporine, which is an alternative spelling of the drug name. Both names refer to the same compound, which is being developed by Novartis AG for the treatment of severe atopic dermatitis.